ArticleESMO real world data and digital oncology2024
READY: REAl-world Data from an Italian compassionate use program of avelumab first-line maintenance for locallY advanced or metastatic urothelial carcinoma.
Article in ESMO real world data and digital oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Trial
- Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Real-World Results From an Early Access Program in Malaysia.Asia-Pacific journal of clinical oncology · 2026Article
- Article
- Real-World Use of Avelumab First-Line Maintenance for Locally Advanced or Metastatic Urothelial Carcinoma in Japan: Treatment Patterns, Effectiveness, and Safety.International journal of urology : official journal of the Japanese Urological Association · 2026Review
- Outcomes with Avelumab Maintenance Treatment for Advanced Urothelial Cancer in a US Patient Cohort.Current oncology (Toronto, Ont.) · 2026Article
- Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario?Frontiers in immunology · 2026Article
- Real-world effectiveness of Avelumab maintenance in advanced urothelial carcinoma: results from the Italian multicenter MALVA study (Meet-URO 25).The oncologist · 2025Observational
- Avelumab maintenance in advanced urothelial carcinoma: real-world data from Northern Spain (AVEBLADDER study).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- JAVEMACS: a real-world study of avelumab maintenance therapy for advanced urothelial carcinoma in Japan.ESMO real world data and digital oncology · 2025Article
- JAVEMACS-D: claims database analysis of avelumab maintenance therapy for advanced urothelial carcinoma in Japan.Scientific reports · 2025Observational
- Article
- Real-World Outcomes of Avelumab Maintenance Therapy in Patients With Curatively Unresectable Urothelial Carcinoma in Japan: Results From the Final Analysis of Postmarketing Surveillance.Cancer medicine · 2025Article
- Treatment strategies for cisplatin-ineligible metastatic bladder cancer: Emerging therapies and future perspectives.Investigative and clinical urology · 2025Review
- Effects of Avelumab Maintenance on Advanced Urothelial Carcinoma: A Real-World Multicenter Study.Cancer medicine · 2025Article
- A Podcast on Real-World Evidence with Avelumab First-Line Maintenance and Treatment Sequencing in Locally Advanced or Metastatic Urothelial Carcinoma.Targeted oncology · 2025Article
- Noninterventional retrospective study of standard-of-care systemic treatment patterns and outcomes in US patients with advanced urothelial carcinoma.The oncologist · 2025Article
- Real-World Retrospective Study of Clinical and Economic Outcomes Among Patients with Locally Advanced or Metastatic Urothelial Carcinoma Treated with First-Line Systemic Anti-Cancer Therapies in the United States: Results from the IMPACT UC-III Study.Current oncology (Toronto, Ont.) · 2025Article
- Maintenance Therapy With Avelumab for Patients With Metastatic Urothelial Carcinoma: A Real-World, Ambispective RAVE-Bladder Study.Cancer medicine · 2025Article
- Review
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Avelumab first-line (1L) maintenance is recommended as the standard of care for patients with locally advanced or metastatic urothelial carcinoma (la/mUC) without disease progression following 1L platinum-based chemotherapy (PBC). We report results from READY, a real-world study of avelumab 1L maintenance in an Italian compassionate use program (CUP). Patients and methods: In this prospective, noninterventional CUP, avelumab was provided on physician's request to patients with la/mUC without disease progression following four to six cycles of 1L PBC, after approval by the local ethics committees, per Italian compassionate use regulations. Results: Between January 2021 and March 2022, 414 patients received avelumab 1L maintenance and were assessable for survival/safety analyses; 79.2% were male and median age was 71 years. At data cut-off (30 July 2023), median follow-up was 20.30 months [95% confidence interval (CI) 19.78-20.93 months]. From the start of avelumab treatment, median overall survival (OS) was 26.22 months [95% CI 19.97 months-not estimable (NE); 12-month OS rate, 65.6%] and median progression-free survival was 7.63 months (95% CI 6.02-9.31 months). In patients who had received 1L carboplatin plus gemcitabine ( Conclusions: In READY, avelumab 1L maintenance showed clinical benefit in patients in Italy with la/mUC without progression following PBC, including across clinical subgroups, further supporting its use as the standard of care in this setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.